Ntrk2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NTRK2 (Neurotrophic Receptor Tyrosine Kinase 2) encodes the BDNF (brain-derived neurotrophic factor) receptor, also known as TrkB. This receptor tyrosine kinase is essential for synaptic plasticity, learning, memory, and neuronal survival. NTRK2 is a major therapeutic target for depression, Alzheimer's disease, and neurodegenerative disorders.
| Property |
Value |
| Gene Symbol |
NTRK2 |
| Full Name |
Neurotrophic Receptor Tyrosine Kinase 2 |
| Chromosomal Location |
9q22.1 |
| NCBI Gene ID |
4915 |
| Ensembl ID |
ENSG00000148018 |
| UniProt ID |
Q16620 |
| OMIM |
600456 |
| Property |
Value |
| Protein Name |
TrkB (Tropomyosin receptor kinase B) |
| Molecular Weight |
~145 kDa (822 amino acids) |
| Subcellular Localization |
Cell membrane, endosomes, synapses |
| Protein Family |
Trk family (TrkA, TrkB, TrkC) |
- Full-length TrkB (TrkB.FL): Functional receptor with tyrosine kinase domain
- Truncated TrkB (TrkB.T1/T2): Dominant-negative isoforms lacking kinase domain
- BDNF receptor: High-affinity binding to BDNF and NT-4/5
- Synaptic plasticity: Long-term potentiation (LTP), dendritic spine formation
- Learning and memory: Critical for hippocampus-dependent memory
- Neuronal survival: Activates PI3K/Akt, MAPK/ERK, and PLCγ pathways
- Axonal guidance: Role in development and regeneration
- BDNF/TrkB signaling is impaired in AD
- Reduced TrkB expression in AD hippocampus
- BDNF therapy may improve synaptic function
- Genetic variants may modify AD risk
- BDNF supports dopaminergic neuron survival
- NTRK2 signaling is neuroprotective in PD models
- AAV-BDNF/TrkB gene therapy approaches
¶ Depression and Anxiety
- Antidepressant effects of BDNF/TrkB signaling
- Ketamine's rapid antidepressant effects via TrkB
- Genetic variants associated with depression
- Rett syndrome: NTRK2 dysregulation
- Huntington's Disease: BDNF/TrkB signaling deficit
- Epilepsy: Altered TrkB expression
| Approach |
Status |
Description |
| BDNF mimetics |
Research |
Small molecule BDNF mimetics |
| TrkB agonists |
Clinical trials |
AAV-BDNF for AD, BDNF mimetics |
| TrkB modulators |
Research |
Positive allosteric modulators |
| Gene therapy |
Preclinical |
AAV-TrkB for PD |
- Huang EJ, Reichardt LF. (2001). Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 24:677-736. https://doi.org/10.1146/annurev.neuro.24.1.677
- Poo MM. (2001). Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2(1):24-32. https://doi.org/10.1038/35049004
- Lu B, et al. (2013). BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 14(6):401-16. https://doi.org/10.1038/nrn3505
- Autry AE, Monteggia LM. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 64(2):238-58. https://doi.org/10.1124/pr.111.005108
- Murer MG, et al. (2001). Brain-derived neurotrophic factor in neurodegenerative diseases. J Neurol Sci. 191(1-2):21-4. https://doi.org/10.1016/s0022-510x(01)00604-3
The study of Ntrk2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] NTRK2/TrkB signaling in neuronal survival. PMID:24790033